iCAD (NASDAQ:ICAD – Get Free Report) is anticipated to release its earnings data before the market opens on Monday, March 10th. Analysts expect iCAD to post earnings of ($0.05) per share and revenue of $4.72 million for the quarter.
iCAD Stock Performance
Shares of NASDAQ ICAD opened at $2.36 on Tuesday. The firm has a market cap of $62.63 million, a price-to-earnings ratio of -18.15 and a beta of 1.47. The business’s 50-day simple moving average is $2.56 and its 200-day simple moving average is $2.00. iCAD has a 52 week low of $1.18 and a 52 week high of $3.78.
Analyst Ratings Changes
Separately, StockNews.com raised iCAD from a “sell” rating to a “hold” rating in a report on Thursday, February 20th.
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Read More
- Five stocks we like better than iCAD
- Are Penny Stocks a Good Fit for Your Portfolio?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Profitably Trade Stocks at 52-Week Highs
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
